Infudopa SubC™ is a levodopa-carbidopa solution that is administered subcutaneously using a portable belt pump and intended as monotherapy for outpatient treatment of Parkinson´s disease with moderate to severe on-off symptoms. Infudopa SubC™ has a pH optimizing levodopa uptake from the subcutaneous tissue and minimizing the risk of side effects at the injection site.
The shelf life for this product is 30 months in refrigerator and a minimum of 3 months at room temperature. This excellent stability represents a considerable logistical advantage for patients, e.g. when travelling.
Dizlin Pharmaceuticals plans to file the application for marketing authorization of Infudopa SubC™ in Europe in 2022 and in the US in 2023.
Infudopa IntraV™ is a levodopa-carbidopa solution intended for treatment of inpatients for which enteral levodopa administration is infeasible, e.g. before or after surgery, as well as for inpatients where marked on-off symptomatology prevents various diagnostics procedures or surgery. It may also be used as rescue therapy in inpatients in an acute state of severe hypokinesia.
Dizlin Pharmaceuticals plans to file the application for marketing authorization of Infudopa IntraV™ in Europe in 2021 and in the US in 2021/2022.
Our journey continues
It is the nature of research & development that the likelihood of success and the time frame for future value-creating events are challenging to predict. The illustration is intended to provide a schematic picture of the next coming years.